# A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

> **NCT03745222** · PHASE3 · TERMINATED · sponsor: **Celgene** · enrollment: 1 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Concurrent chemoradiotherapy (cCRT)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03745222
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-22
- **Primary completion:** 2019-06-26
- **Final completion:** 2019-06-26
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound, pending the acquisition of Celgene by Bristol Myers Squibb
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745222, "A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03745222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*